Drug Profile
Atomoxetine oral solution - TAHO Pharmaceuticals
Alternative Names: TAH-9922Latest Information Update: 30 Oct 2023
Price :
$50
*
At a glance
- Originator TAHO Pharmaceuticals
- Class Behavioural disorder therapies; Propylamines
- Mechanism of Action Adrenergic uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Attention-deficit hyperactivity disorder